Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
ZeptoMetrix an Antylia scientific company

Download Mobile App




Analysis Software Identifies DNA Variants for Individuated Cancer Research

By LabMedica International staff writers
Posted on 19 Jan 2012
The ability to identify causal variants from the output of a whole genome or exome sequencing research remains a key hurdle for making scientific breakthroughs and realizing the benefit of next-generation sequencing (NGS). More...
To address these challenges, a knowledge base of accurate, curated biologic content and an extremely comprehensive database of curated mutation data have been developed.

The Ingenuity Variant Analysis web application, which is currently available in limited access, enables researchers to rapidly weed through millions of variants to identify a few causal variants based upon known relationships with pathways, genes, biologic processes, and diseases.

Ingenuity Systems (Redwood City, CA, USA), a provider of information and analysis solutions for life-science researchers, announced that Translational Oncology at University Medical Center Mainz (TRON; Germany) has used Ingenuity Variant Analysis to identify cancer driver variants that inform on the development of a research customized RNA-based therapeutic agent.

“Individualized therapy development is about speed and accuracy. As scientists and clinicians explore new avenues for truly individualized cancer therapy and personalized medicine, it is critical to have tools that help us quickly prioritize cancer driver variants for treatment of a particular patient,” stated John Castle, co-head of the TRON Biomarker Development Center. “Ingenuity Variant Analysis helped us identify 30 compelling tumor-specific variants in record time that we then used to inform our first experimental therapeutic RNA cocktail.”

“TRON researchers are pioneers in the application of NGS technology,” said Doug Bassett, PhD, chief scientific officer and chief technology officer, Ingenuity Systems. “This is a promising approach that could provide a potent new weapon in the fight against cancer, training patients’ own immune systems to fight tumor cells. We are proud that Ingenuity Variant Analysis is able to play a critical role in the fight against genetic disease.”

Ingenuity Variant Analysis is a web application that enables researchers to identify causal variants from human resequencing data in just minutes using known information about the biological effects of variants. Ingenuity Variant Analysis uses the accurate, curated biologic content in the Ingenuity Knowledge Base, plus many additional sources of variant-level content, to help researchers studying genetics and disease biology quickly sift through millions of variants to identify a few causal variants based upon known relationships with pathways, genes, biological processes, and diseases.

Related Links:
Ingenuity Systems
TRON


Platinum Member
ADAMTS-13 Protease Activity Test
ATS-13 Activity Assay
Verification Panels for Assay Development & QC
Seroconversion Panels
Complement 3 (C3) Test
GPP-100 C3 Kit
Gold Member
Automated Staining Unit
RAL Stainer
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: QIP-MS could predict and detect myeloma relapse earlier compared to currently used techniques (Photo courtesy of Adobe Stock)

Mass Spectrometry-Based Monitoring Technique to Predict and Identify Early Myeloma Relapse

Myeloma, a type of cancer that affects the bone marrow, is currently incurable, though many patients can live for over 10 years after diagnosis. However, around 1 in 5 individuals with myeloma have a high-risk... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Technology

view channel
Image: Ziyang Wang and Shengxi Huang have developed a tool that enables precise insights into viral proteins and brain disease markers (Photo courtesy of Jeff Fitlow/Rice University)

Light Signature Algorithm to Enable Faster and More Precise Medical Diagnoses

Every material or molecule interacts with light in a unique way, creating a distinct pattern, much like a fingerprint. Optical spectroscopy, which involves shining a laser on a material and observing how... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.